Paul Carter is a Genentech Fellow in Antibody Engineering, with a distinguished career recognized by membership in the US National Academy of Engineering since 2022 for contributions to antibody therapeutics. They co-invented an approved antibody therapeutic and have developed humanization technologies for over nine approved therapies that benefit millions globally. With a rich history at organizations like Seattle Genetics and Amgen, they have overseen the discovery of more than 35 antibody-based drug candidates and have an extensive publication record, authoring over 119 scientific papers. Carter holds a PhD in Molecular Biology and has been instrumental in organizing numerous international conferences on protein and antibody engineering.
This person is not in the org chart
This person is not in any teams
This person is not in any offices